An International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes, And Resource Use in Patients with Multiple Myeloma (INTEGRATE)

Study identification

• EU PAS number:
  EUPAS21846
• Study ID:
  46405
• Official title and acronym:
  An International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes, And Resource Use in Patients with Multiple Myeloma (INTEGRATE)
• DARWIN EU® study:
  No
• Study countries:
  Argentina

  Australia

  China

  Colombia

  Hong Kong

  Korea, Republic of

  Mexico

  Russian Federation

  Saudi Arabia

  Singapore

  South Africa

  Taiwan

  Türkiye
• Study description:
  The purpose of this study is to describe time to next treatment at each line of therapy in participants receiving frontline treatment for newly diagnosed Multiple Myeloma (NDMM), Cohort 1, and in participants with relapsed or refractory MM (RRMM), Cohort 2.
• Study status:
  Finalised

Research institutions and networks

Institutions

Takeda

Multiple centres: 70 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned: 30/03/2018

Actual: 03/02/2017

Study start date

Planned: 30/03/2018

Actual: 21/03/2018

Data analysis start date

Planned: 20/03/2021

Actual: 30/03/2021

Date of final study report

Planned: 24/11/2021

Actual: 10/12/2021

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Takeda

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable